Berberine chloride hydrate
Based on 75 publication(s) in Google Scholar
Berberine chloride hydrate (Natural Yellow 18 chloride hydrate) is an alkaloid that acts as an antibiotic. Berberine chloride hydrate induces reactive oxygen species (ROS) generation and inhibits DNA topoisomerase. Antineoplastic properties.
For research use only. We do not sell to patients.
- Purity: 99.69%
- CAS No.: 68030-18-2
- Formula: C20H20ClNO5
- Molecular Weight:389.83
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications Citing Use of MedChemExpress (MCE) Berberine chloride hydrate
More- Cell Stem Cell. 2025 Mar 20:S1934-5909(25)00084-0. [Abstract]
- Nat Commun. 2025 Jan 2;16(1):212. [Abstract]
- Acta Pharm Sin B. 2025 Sep;15(9):4789-4806. [Abstract]
- Adv Sci (Weinh). 2026 Mar;13(16):e13310. [Abstract]
- J Hazard Mater. 2026 Mar 15:506:141417. [Abstract]
- NPJ Biofilms Microbiomes. 2025 Jul 1;11(1):120. [Abstract]
- Int J Biol Macromol. 2025 May 21:144496. [Abstract]
- Acta Pharmacol Sin. 2023 Feb;44(2):332-344. [Abstract]
- Phytomedicine. 2025 Dec 7:150:157678. [Abstract]
- Phytomedicine. 2025 Sep 4:148:157233. [Abstract]
- Phytomedicine. 2025 Apr:139:156517. [Abstract]
- Phytomedicine. 2024 Dec:135:156111. [Abstract]
- Phytomedicine. 2024 Jan:123:155247. [Abstract]
- Phytomedicine. 2023 Sep:118:154962. [Abstract]
- NPJ Sci Food. 2025 Feb 4;9(1):16. [Abstract]
- Biomed Pharmacother. 2024 Jan:170:116012. [Abstract]
- Int J Nanomedicine. 2023 Jul 31:18:4347-4363. [Abstract]
- Mol Med. 2024 Dec 20;30(1):251. [Abstract]
- Dent Mater. 2026 May;42(5):898-911. [Abstract]
- JCI Insight. 2023 Jul 24;8(14):e166306. [Abstract]
- Chin Med. 2025 Nov 17;20(1):190. [Abstract]
- Biochem Pharmacol. 2021 Jun:188:114576. [Abstract]
- J Ethnopharmacol. 2024 Apr 24:324:117829. [Abstract]
- J Ethnopharmacol. 2022 Mar 1:285:114786. [Abstract]
- Inflammopharmacology. 2024 May 17. [Abstract]
- Mech Ageing Dev. 2020 Oct;191:111347. [Abstract]
- CNS Neurosci Ther. 2025 Feb;31(2):e70253. [Abstract]
- Int J Mol Sci. 2026 Jan 21;27(2):1063. [Abstract]
- Front Pharmacol. 2023 Apr 18:14:1148611. [Abstract]
- Pharm Biol. 2024 Dec;62(1):53-61. [Abstract]
- Int Immunopharmacol. 2024 Sep 24;142(Pt B):113227. [Abstract]
- Int Immunopharmacol. 2024 May 29:136:112278. [Abstract]
- Molecules. 2024 May 14;29(10):2304. [Abstract]
- Hepatol Commun. 2024 Mar 29;8(4):e0405. [Abstract]
- Drug Dev Res. 2026 Feb;87(1):e70223. [Abstract]
- J Cell Mol Med. 2025 Sep;29(17):e70836. [Abstract]
- J Food Biochem. 2025 Jul 16.
- Biochim Biophys Acta Mol Basis Dis. 2025 May 22:167920. [Abstract]
- J Inflamm Res. 2025 Aug 21:18:11451-11461. [Abstract]
- Sci Rep. 2025 Jul 1;15(1):21623. [Abstract]
- Fish Shellfish Immunol. 2024 Jun:149:109522. [Abstract]
- Sci Rep. 2022 Oct 17;12(1):17350. [Abstract]
- Aquacult Nutr. 14 Jul 2022.
- Aquaculture. 15 May 2022, 738055.
- Microbiol Spectr. 2023 Sep 25;11(5):e0217023. [Abstract]
- Cell Signal. 2025 Jul:131:111732. [Abstract]
- Microb Pathog. 2025 Dec:209:108114. [Abstract]
- Exp Cell Res. 2024 May 13:114094. [Abstract]
- Food Chem Toxicol. 2023 May:175:113743. [Abstract]
- Mol Med Rep. 2023 Jan;27(1):17. [Abstract]
- Exp Cell Res. 2020 Aug 1;393(1):112054. [Abstract]
- Toxicol Appl Pharmacol. 2025 Sep 13:505:117563. [Abstract]
- Appl Biochem Biotechnol. 2024 Aug;196(8):5265-5282. [Abstract]
- J Pharm Pharmacol. 2022 Sep 1;74(9):1353-1363. [Abstract]
- J Appl Microbiol. 2021 Apr;130(4):1154-1172. [Abstract]
- Cardiovasc Drugs Ther. 2022 Aug;36(4):633-643. [Abstract]
- J Appl Toxicol. 2024 Nov;44(11):1700-1713. [Abstract]
- Vet Microbiol. 2026 May:316:110992. [Abstract]
- Toxicol In Vitro. 2025 Dec:109:106128. [Abstract]
- BMC Pharmacol Toxicol. 2023 May 11;24(1):29. [Abstract]
- Oncologie. 2023 Mar 10.
- Gene. 2022 Mar 30:816:146171. [Abstract]
- Oncol Lett. 2025 Dec 1;31(2):62. [Abstract]
- J Bone Miner Metab. 2021 Sep;39(5):748-756. [Abstract]
- Arch Oral Biol. 2026 Mar:183:106496. [Abstract]
- Biol Pharm Bull. 2022 Oct 1;45(10):1444-1451. [Abstract]
- Lett Drug Des Discov. 2025 Dec 13.
- Res Sq. 2025 Apr 15.
- Genome Instab Dis. 2025 Mar.
- SSRN. 2023 Jan 27.
- Research Square Print. 2022 Aug.
- Research Square Preprint. 2021 Sep.
- Research Square Preprint. 2021 Jun.
- Research Square Preprint. 2021 May.
- Evid Based Complement Alternat Med. 2021 May 4:2021:6688629. [Abstract]
-
In Vivo Efficacy Study
-
RT-PCR
-
Bio/Physico-chemical Assay
-
IF
-
Others
All Topoisomerase Isoforms
MoreAll Antibiotic Isoforms
MoreAll Endogenous Metabolite Isoforms
MoreAll Parasite Isoforms
More
Biological Activity
Berberine chloride hydrate ( Natural Yellow 18 chloride hydrate; 1.25-160 μM; 72 hours) has potential inhibitory effects on the proliferation of four colorectal carcinoma cell lines LoVo, HCT116, SW480, and HT-29[1].
Berberine chloride hydrate (1.25-160 μM; 24-72 hours) induces a time- and dose-dependent inhibition of LoVo cell growth[1].
LoVo cells are exposure to Berberine chloride hydrate (10-80 μM) for 24 h. Cell cycle analysis of 40 μM Berberine-treated LoVo cells by flow cytometry shows accumulation of cells in the G2/M phase[1].
Berberine chloride hydrate (10-80 μM) suppresses cyclin B1, cdc2 and cdc25c protein expression after 24 h, especially at the dose of 80.0 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Four colorectal carcinoma cell lines LoVo, HCT116, SW480, and HT-29
-
Concentration:1.25, 2.5, 5, 10, 20, 40, 80, and 160 μM
-
Incubation Time:72 hours
-
Result:Inhibited the proliferation of four cell lines. The IC50 ranged from 40.8±4.1 μM (LoVo) to 98.6±2.9 μM (HCT116).
-
Cell Line:Colorectal carcinoma cell lines LoVo
-
Concentration:1.25, 2.5, 5, 10, 20, 40, 80, and 160 μM
-
Incubation Time:24, 48, 72 hours
-
Result:Induced a time- and dose-dependent inhibition of cell growth. By 72 h, 160.0 μM induced 71.1±1.9 % growth inhibitions in LoVo cells.
-
Cell Line:LoVo cells
-
Concentration:0, 10, 20, 40, or 80 μM
-
Incubation Time:24 hours
-
Result:Exposure to 40.0 μM induced G2/M-phase cell cycle arrest, an increase in the G2/M-phase population and a progressive decline in the G1 population.
-
Cell Line:LoVo cells
-
Concentration:10, 20, 40, or 80 μM
-
Incubation Time:24 hours
-
Result:Suppressed cyclin B1, cdc2 and cdc25c protein expression.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:5-week-old BALB/c nu/nu mice with human colorectal adenocarcinoma LoVo xenografts[1]
-
Dosage:10, 30, or 50 mg/kg/day
-
Administration:Gastrointestinal gavage; for 10 consecutive days
-
Result:Showed inhibitory rates of 33.1 % and 45.3 % at doses of 30 and 50 mg/kg/day.
Chemical Information
-
CAS No. 68030-18-2
-
Appearance Solid
-
Molecular Weight 389.83
-
Formula C20H20ClNO5
-
Color Light yellow to yellow
-
SMILES
COC1=C(OC)C2=C[N+]3=C(C(C(CC3)=C4)=CC5=C4OCO5)C=C2C=C1.[Cl-].O
-
Synonyms
Natural Yellow 18 chloride hydrate
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (75)
-
Journal Impact Factor
-
Most Recent
-
Cell Stem Cell
Vagal pathway activation links chronic stress to decline in intestinal stem cell function. [Abstract]2025 Mar 20:S1934-5909(25)00084-0. PMID: 40120585 -
Nat Commun
Mitochondrial-cytochrome c oxidase II promotes glutaminolysis to sustain tumor cell survival upon glucose deprivation. [Abstract]2025 Jan 2;16(1):212. PMID: 39747079
Berberine chloride hydrate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 2;16(1):212. [Abstract]
A549 (1 ×106) cells were subcutaneously inoculated into the right scruff of the female BALB/c nude mouse (n = 8/group). On day 22 after inoculation, mice were given Berberine (p.o.; 40 mg/kg; daily for 12 days) . The tumor volumes on indicated days after gavage were examined
Berberine chloride hydrate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 2;16(1):212. [Abstract]
H1299 cells were treated with or without Berberine (Ber;5 μM; 24 h). Cells were subjected to qPCR (n = 3 independent experiments) analyses.
-
Acta Pharm Sin B
Palmitoylated SARM1 targeting P4HA1 promotes collagen deposition and myocardial fibrosis: A new target for anti-myocardial fibrosis. [Abstract]2025 Sep;15(9):4789-4806. PMID: 41049740
Berberine chloride hydrate purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2025 Sep;15(9):4789-4806. [Abstract]
The hydroxyproline assay kit was used to detect the secretion of fibroblast collagen in NMCFs by Berberine (BBC; 70 μM). n=3-4. *P< 0.05, **P< 0.01 vs. CTL #P<0.05, ###P <0.001 vs. TGF-β1.
Berberine chloride hydrate purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2025 Sep;15(9):4789-4806. [Abstract]
Immunofluorescence in determining the expression of P4HA1 after treated with Berberine (BBC; p.o.; 20 mg/kg for 7 days ) and Selonsertib (p.o.; 20 mg/kg for 7 days ) in the heart tissue of MI mice. n=3. *P < 0.05, **P < 0.01 vs. Sham, #P < 0.05, ##P < 0.01 vs. MI. Scale bar, 200 µm.
Berberine chloride hydrate purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2025 Sep;15(9):4789-4806. [Abstract]
Echocardiographic detection of cardiac function changes in MI mice and treated with Berberine (BBC; p.o.; 20 mg/kg for 7 days ) and Selonsertib (p.o.; 20 mg/kg for 7 days ) . n=3-4. *P < 0.05 vs. Sham, #P < 0.05 vs. MI.
-
Adv Sci (Weinh)
2026 Mar;13(16):e13310. PMID: 41589654 -
J Hazard Mater
Ammonia-induced exosomal miRNA disrupts autophagy and promotes lung injury: Therapeutic potential of natural compounds. [Abstract]2026 Mar 15:506:141417. PMID: 41775203 -
NPJ Biofilms Microbiomes
Berberine chloride hydrate impairs Streptococcus mutans biofilm formation via inhibiting sortase A activity. [Abstract]2025 Jul 1;11(1):120. PMID: 40595693 -
Int J Biol Macromol
Berberine@AgNPs@Carboxylated chitosan hydrogel dressing with immunomodulatory and anti-biofilm properties promotes wound repair in drug-resistant bacterial infections. [Abstract]2025 May 21:144496. PMID: 40409636 -
Acta Pharmacol Sin
2023 Feb;44(2):332-344. PMID: 35948750 -
Phytomedicine
Berberine facilitates alveolar bone regeneration via Ptgs2-mediated dual regulation of osteoblast differentiation and fibroblast inhibition. [Abstract]2025 Dec 7:150:157678. PMID: 41401587 -
Phytomedicine
Huang-Lian-Jie-Du decoction enhances Capecitabine-Oxaliplatin efficacy via Akkermansia muciniphila and CD8+ T cells in colorectal cancer. [Abstract]2025 Sep 4:148:157233. PMID: 40972261 -
Phytomedicine
Berberine protects against dysentery by targeting both Shigella filamentous temperature sensitive protein Z and host pyroptosis: Resolving in vitro-vivo effect discrepancy. [Abstract]2025 Apr:139:156517. PMID: 39986228 -
Phytomedicine
Swiprosin-1 participates in the berberine-regulated AMPK/MLCK pathway to attenuate colitis-induced tight junction damage. [Abstract]2024 Dec:135:156111. PMID: 39369569 -
Phytomedicine
Modified Hu-lu-ba-wan protects diabetic glomerular podocytes via promoting PKM2-mediated mitochondrial dynamic homeostasis. [Abstract]2024 Jan:123:155247. PMID: 38128393 -
Phytomedicine
2023 Sep:118:154962. PMID: 37506403 -
NPJ Sci Food
2025 Feb 4;9(1):16. PMID: 39900946 -
Biomed Pharmacother
Berberine exerts antidepressant effects in vivo and in vitro through the PI3K/AKT/CREB/BDNF signaling pathway. [Abstract]2024 Jan:170:116012. PMID: 38113631 -
Int J Nanomedicine
Combined Therapy of Experimental Autoimmune Uveitis by a Dual-Drug Nanocomposite Formulation with Berberine and Dexamethasone. [Abstract]2023 Jul 31:18:4347-4363. PMID: 37545873 -
Mol Med
Berberine promotes primordial follicle activation and increases ovulated oocyte quantity in aged mice. [Abstract]2024 Dec 20;30(1):251. PMID: 39707173 -
Dent Mater
Injectable, regenerative and anti-infective PEGylated polyglycerol sebacate-modified calcium phosphate cements triggered by berberine and rhBMP-2 for oral bone defect repair. [Abstract]2026 May;42(5):898-911. PMID: 41633879 -
JCI Insight
Age-related decline in hippocampal tyrosine phosphatase PTPRO is a mechanistic factor in chemotherapy-related cognitive impairment. [Abstract]2023 Jul 24;8(14):e166306. PMID: 37485875 -
Chin Med
Berberine ameliorates high-fat diet-induced metabolic disorders through promoting gut Akkermansia and modulating bile acid metabolism. [Abstract]2025 Nov 17;20(1):190. PMID: 41243097 -
Biochem Pharmacol
Berberine exerts anti-tumor activity in diffuse large B-cell lymphoma by modulating c-myc/CD47 axis. [Abstract]2021 Jun:188:114576. PMID: 33930347 -
J Ethnopharmacol
Jiao-tai-wan and its effective component-berberine improve diabetes and depressive disorder through the cAMP/PKA/CREB signaling pathway. [Abstract]2024 Apr 24:324:117829. PMID: 38296172 -
J Ethnopharmacol
Exploring the pathogenesis of type 2 diabetes mellitus intestinal damp-heat syndrome and the therapeutic effect of Gegen Qinlian Decoction from the perspective of exosomal miRNA. [Abstract]2022 Mar 1:285:114786. PMID: 34763043 -
Inflammopharmacology
Berberine mitigates diclofenac-induced intestinal mucosal mechanical barrier dysfunction through the restoration of autophagy by inhibiting exosome-mediated lncRNA H19. [Abstract]2024 May 17. PMID: 38758516 -
Mech Ageing Dev
AMPK alleviates oxidative stress‑induced premature senescence via inhibition of NF-κB/STAT3 axis-mediated positive feedback loop. [Abstract]2020 Oct;191:111347. PMID: 32882228 -
CNS Neurosci Ther
Berberine Alleviates Kainic Acid-Induced Acute Epileptic Seizures in Mice via Reshaping Gut Microbiota-Associated Lipid Metabolism. [Abstract]2025 Feb;31(2):e70253. PMID: 39915895 -
Int J Mol Sci
Berberine Alleviates Shigella-Induced Dysentery by Regulating Intestinal Barrier and Inflammatory Responses. [Abstract]2026 Jan 21;27(2):1063. PMID: 41596706 -
Front Pharmacol
Berberine stimulates lysosomal AMPK independent of PEN2 and maintains cellular AMPK activity through inhibiting the dephosphorylation regulator UHRF1. [Abstract]2023 Apr 18:14:1148611. PMID: 37144221 -
Pharm Biol
Berberine decreases S100B generation to regulate gut vascular barrier permeability in mice with burn injury. [Abstract]2024 Dec;62(1):53-61. PMID: 38108311 -
Int Immunopharmacol
Berberine attenuates neuronal ferroptosis via the AMPK-NRF2-HO-1-signaling pathway in spinal cord-injured rats. [Abstract]2024 Sep 24;142(Pt B):113227. PMID: 39321704 -
Int Immunopharmacol
Berberine enhances the function of intestinal stem cells in healthy and radiation-injured mice. [Abstract]2024 May 29:136:112278. PMID: 38815353 -
Molecules
Discovery of Nine Dipeptidyl Peptidase-4 Inhibitors from Coptis chinensis Using Virtual Screening, Bioactivity Evaluation, and Binding Studies. [Abstract]2024 May 14;29(10):2304. PMID: 38792165 -
Hepatol Commun
Oxyberberine sensitizes liver cancer cells to sorafenib via inhibiting NOTCH1-USP7-c-Myc pathway. [Abstract]2024 Mar 29;8(4):e0405. PMID: 38573832 -
Drug Dev Res
Polydatin Protects Against the Formation of PPE-Induced Abdominal Aortic Aneurysms in Mice by Activating Nuclear Factor Erythroid 2-Related Factor 2. [Abstract]2026 Feb;87(1):e70223. PMID: 41486502 -
J Cell Mol Med
Berberine Sensitises Breast Cancer Cells to Radiation via the Attenuation of DNA Ligase III. [Abstract]2025 Sep;29(17):e70836. PMID: 40916080 -
-
Biochim Biophys Acta Mol Basis Dis
Berberine chloride alleviated intestinal inflammation and improved postoperative ileus by regulating macrophage polarization via PI3K/AKT signaling pathway. [Abstract]2025 May 22:167920. PMID: 40412730 -
J Inflamm Res
Berberine Inhibits Acne-Related Lipid Secretion and Inflammation by Regulating the hsa-miR-3150a-3p/TP53 Pathway. [Abstract]2025 Aug 21:18:11451-11461. PMID: 40860941 -
Sci Rep
Ursolic and oleanolic acids suppress MNNG induced malignant transformation of human gastric mucosal epithelium by regulating the PI3 K/AKT pathway. [Abstract]2025 Jul 1;15(1):21623. PMID: 40594240 -
Fish Shellfish Immunol
Berberine inhibits SGIV replication by suppressing inflammatory response and oxidative stress. [Abstract]2024 Jun:149:109522. PMID: 38548190 -
Sci Rep
Enhanced CHOLESTEROL biosynthesis promotes breast cancer metastasis via modulating CCDC25 expression and neutrophil extracellular traps formation. [Abstract]2022 Oct 17;12(1):17350. PMID: 36253427 -
-
-
Microbiol Spectr
The inhibitory effect of berberine chloride hydrate on Streptococcus mutans biofilm formation at different pH values. [Abstract]2023 Sep 25;11(5):e0217023. PMID: 37747238 -
Cell Signal
Inhibition of N6-methyladenosine methylation of ASC by berberine ameliorates pyroptosis of renal tubular epithelial cells in acute kidney injury. [Abstract]2025 Jul:131:111732. PMID: 40074191 -
Microb Pathog
Berberine inhibits Mycoplasma synoviae infection by suppressing PIK3CA-dependent inflammatory and apoptotic responses in avian macrophages. [Abstract]2025 Dec:209:108114. PMID: 41115537 -
Exp Cell Res
Berberine increases the killing effect of pirarubicin on HCC cells by inhibiting ATG4B-autophagy pathway. [Abstract]2024 May 13:114094. PMID: 38750718 -
Food Chem Toxicol
Berberine attenuates sunitinib-induced cardiac dysfunction by normalizing calcium regulation disorder via SGK1 activation. [Abstract]2023 May:175:113743. PMID: 36972840 -
Mol Med Rep
Triptolide promotes ferroptosis by suppressing Nrf2 to overcome leukemia cell resistance to doxorubicin. [Abstract]2023 Jan;27(1):17. PMID: 36453238 -
Exp Cell Res
Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]2020 Aug 1;393(1):112054. PMID: 32376287 -
Toxicol Appl Pharmacol
Berberine alleviates acute embolism-induced lung inflammation and injury by suppressing miR-22-5p expression and modulating the TLR4/NF-κB signaling pathway. [Abstract]2025 Sep 13:505:117563. PMID: 40953642 -
Appl Biochem Biotechnol
Berberine Protects Against Dihydrotestosterone-Induced Human Ovarian Granulosa Cell Injury and Ferroptosis by Regulating the Circ_0097636/MiR-186-5p/SIRT3 Pathway. [Abstract]2024 Aug;196(8):5265-5282. PMID: 38153651 -
J Pharm Pharmacol
Berberine suppresses the migration and invasion of colon cancer cells by inhibition of lipogenesis through modulation of promyelocytic leukemia zinc finger-mediated sterol-regulatory element binding proteins cleavage-activating protein ubiquitination. [Abstract]2022 Sep 1;74(9):1353-1363. PMID: 35641094 -
J Appl Microbiol
Enhanced in vitro antimicrobial activity of amphotericin B with berberine against dual-species biofilms of Candida albicans and Staphylococcus aureus. [Abstract]2021 Apr;130(4):1154-1172. PMID: 32996236 -
Cardiovasc Drugs Ther
Berberine Reverses Nitroglycerin Tolerance through Suppressing Protein Kinase C Alpha Activity in Vascular Smooth Muscle Cells. [Abstract]2022 Aug;36(4):633-643. PMID: 34319490 -
J Appl Toxicol
Berberine prevents against myocardial injury induced by acute β-adrenergic overactivation in rats. [Abstract]2024 Nov;44(11):1700-1713. PMID: 38981847 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607 -
Toxicol In Vitro
Inhibitory potential of phytochemicals on species-specific breast cancer resistance protein transport activity. [Abstract]2025 Dec:109:106128. PMID: 40796067 -
BMC Pharmacol Toxicol
2023 May 11;24(1):29. PMID: 37170144
Berberine chloride hydrate purchased from MedChemExpress. Usage Cited in: BMC Pharmacol Toxicol. 2023 May 11;24(1):29. [Abstract]
Berberine (BBR; 2.5, 5, 10 µM; 48 h) inhibits EGFR phosphorylation in a dose-dependent matter in A431cells.
Berberine chloride hydrate purchased from MedChemExpress. Usage Cited in: BMC Pharmacol Toxicol. 2023 May 11;24(1):29. [Abstract]
Berberine (BBR; 2.5 µM; 10 days) significantly inhibits NCI-H441 colony formation.
Berberine chloride hydrate purchased from MedChemExpress. Usage Cited in: BMC Pharmacol Toxicol. 2023 May 11;24(1):29. [Abstract]
Berberine (BBR; 0.625, 1.25, 2.5, 5, 10 µM; 48 h) inhibits the viability of A431cells in a dose-dependent matter.
-
-
Gene
Pharmacotranscriptomic profiling of resistant triple-negative breast cancer cells treated with lapatinib and berberine shows upregulation of PI3K/Akt signaling under cytotoxic stress. [Abstract]2022 Mar 30:816:146171. PMID: 35026293 -
Oncol Lett
Genome-wide CRISPR screening identifies CLDN1 as a central node in the anticancer mechanisms of berberine and as a therapeutic target in lung cancer. [Abstract]2025 Dec 1;31(2):62. PMID: 41383979 -
J Bone Miner Metab
2021 Sep;39(5):748-756. PMID: 33829324 -
Arch Oral Biol
Investigating the mechanism of berberine in inhibiting periodontitis progression using machine learning, molecular docking, and experimental validation. [Abstract]2026 Mar:183:106496. PMID: 41544413 -
Biol Pharm Bull
Berberine Encapsulated in Exosomes Derived from Platelet-Rich Plasma Promotes Chondrogenic Differentiation of the Bone Marrow Mesenchymal Stem Cells via the Wnt/β-Catenin Pathway. [Abstract]2022 Oct 1;45(10):1444-1451. PMID: 35858798 -
-
-
-
-
-
-
-
-
Evid Based Complement Alternat Med
2021 May 4:2021:6688629. PMID: 34055022
Solvent & Solubility
DMSO : ≥ 3.9 mg/mL (10.00 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 1 mg/mL (2.57 mM; ultrasonic and warming and heat to 60°C)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.5652 mL | 12.8261 mL | 25.6522 mL | 64.1305 mL |
| DMSO | 5 mM | 0.5130 mL | 2.5652 mL | 5.1304 mL | 12.8261 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.